Eir Ventures invests in Henlez

Henlez mission is to transform the management of skin conditions by using enzymes.
Henlez’s pre-clinical lead development program, HEN-001, is an enzyme-based, topical application directed towards hidradenitis suppurativa (HS) – a highly stigmatizing and chronic inflammatory condition characterized by severe pain, malodorous drainage and permanent scarring of the armpits and groin. The company was founded 2019 by former Novozymes A/S scientist and current CEO Jeppe Mouritsen.

Read the full Press Release here